Background: Forensic autopsy strategies may improve differential diagnostics both post-mortem and ante-mortem and aid in clinical settings concerning preventive efforts for premature mortality. Excess mortality and reduced life expectancy affect persons with severe mental illnesses (SMI) for multi-faceted reasons that remain controversial. Somatic conditions, medical treatment and lifestyle diseases, which are primarily examined in the living, contribute to premature deaths. The underlying pathophysiological mechanisms are unclear, though, and the benefits of a focused, standardised autopsy remain unproven. We have developed and implemented an optimised molecular–biological autopsy for deceased persons with SMI. Our aim is to map the occurrence of 1) somatic diseases and organ changes; 2) metabolic syndrome; 3) use and abuse of alcohol, pharmaceuticals and psychoactive substances; 4) pharmacokinetic and pharmacodynamic factors in the metabolism of pharmaceuticals; and 5) genetic variations (acquired and/or congenital) in sudden cardiac death. Additionally, we hope to contribute to diagnostic treatments and preventive measures to benefit those living with SMI. Methods: SURVIVE: let the dead help the living is a prospective, autopsy-based study on 500 deceased persons with SMI subjected to forensic autopsies under the Danish Act on Forensic Inquests and Autopsy. The autopsies followed an extended, standardised autopsy protocol comprised of whole-body computed tomography scanning, magnetic resonance imaging of the heart and brain and an extended forensic autopsy, including a wide panel of analyses (toxicology, microbiology, genetics, histology and biochemical analysis). Additionally, post-mortem data were linked to ante-mortem health data extracted from Danish national health registers.
Discussion: The SURVIVE autopsy procedure, including tissue sampling and bio banking, has been shown to be effective. We expect that the SURVIVE study will provide unique opportunities to unravel the mechanisms and causes of premature death in persons with SMI. We also expect that identifying prognostic biomarkers for comorbidities will contribute to prevention of premature deaths and comorbidities in persons with SMI.
If the inline PDF is not rendering correctly, you can download the PDF file here.
 Thomsen JL, Banner J: Der dør for mange psykiatriske patienter: Sundhedsstyrelsen bør se nærmere på registreringen af dødsårsager. Ugeskrift for læger 2010, 172(33):2256-2257.
 Organization WH: The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines, vol. 1: World Health Organization; 1992.
 Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine HE, Charlson FJ, Norman RE, Flaxman AD, Johns N et al: Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet 2013, 382(9904):1575-1586.
 Wahlbeck K, Westman J, Nordentoft M, Gissler M, Laursen TM: Outcomes of Nordic mental health systems: life expectancy of patients with mental disorders. The British Journal of Psychiatry 2011, 199(6):453-458.
 Laursen TM, Musliner KL, Benros ME, Vestergaard M, Munk-Olsen T: Mortality and life expectancy in persons with severe unipolar depression. Journal of Affective Disorders, 193:203-207.
 Nordentoft M, Wahlbeck K, Hällgren J, Westman J, Ösby U, Alinaghizadeh H, Gissler M, Laursen TM: Excess Mortality, Causes of Death and Life Expectancy in 270,770 Patients with Recent Onset of Mental Disorders in Denmark, Finland and Sweden. PLOS ONE 2013, 8(1):e55176.
 Chang CK, Hayes RD, Broadbent M, Fernandes AC, Lee W, Hotopf M, Stewart R: All-cause mortality among people with serious mental illness (SMI), substance use disorders, and depressive disorders in southeast London: a cohort study. BMC Psychiatry 2010, 10:77.
 Tiihonen J, Lonnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, Haukka J: 11-year follow-up of mortality in patients with schizophrenia: a populationbased cohort study (FIN11 study). Lancet 2009, 374(9690):620-627.
 Leucht S, Burkard T, Henderson J, Maj M, Sartorius N: Physical illness and schizophrenia: a review of the literature. Acta Psychiatr Scand 2007, 116(5):317-333.
 Brown S, Inskip H, Barraclough B: Causes of the excess mortality of schizophrenia. Br J Psychiatry 2000, 177:212-217.
 De Hert M, Detraux J, van Winkel R, Yu W, Correll CU: Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 2011, 8(2):114-126.
 Oud MJ, Meyboom-de Jong B: Somatic diseases in patients with schizophrenia in general practice: their prevalence and health care. BMC Fam Pract 2009, 10:32.
 Megna JL, Schwartz TL, Siddiqui UA, Herrera Rojas M: Obesity in adults with serious and persistent mental illness: a review of postulated mechanisms and current interventions. Ann Clin Psychiatry 2011, 23(2):131-140.
 Vancampfort D, Stubbs B, Mitchell AJ, De Hert M, Wampers M, Ward PB, Rosenbaum S, Correll CU: Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry 2015, 14(3):339-347.
 Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, Rinfret S, Schiffrin EL, Eisenberg MJ: The Metabolic Syndrome and Cardiovascular Risk: A Systematic Review and Meta-Analysis. Journal of the American College of Cardiology 2010, 56(14):1113-1132.
 Weeke P, Jensen A, Folke F, Gislason GH, Olesen JB, Andersson C, Fosbol EL, Larsen JK, Lippert FK, Nielsen SL et al: Antidepressant use and risk of out-of-hospital cardiac arrest: a nationwide case-time-control study. Clin Pharmacol Ther 2012, 92(1):72-79.
 Ray WA, Chung CP, Murray KT, Hall K, Stein CM: Atypical Antipsychotic Drugs and the Risk of Sudden Cardiac Death. The New England journal of medicine 2009, 360(3):225-235.
 Wu CS, Tsai YT, Tsai HJ: Antipsychotic Drugs and the Risk of Ventricular Arrhythmia and/or Sudden Cardiac Death: A Nation-wide Case-Crossover Study. Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease 2015, 4(2):e001568.
 Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC, Jr. et al: Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120(16):1640-1645.
 Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. The Lancet 2013, 381(9875):1371-1379.
 Newcomer JW: Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005, 19 Suppl 1:1-93.
 Beijer U, Andreasson A, Agren G, Fugelstad A: Mortality, mental disorders and addiction: a 5-year follow-up of 82 homeless men in Stockholm. Nord J Psychiatry 2007, 61(5):363-368.
 Nyhlén A, Fridell M, Bäckström M, Hesse M, Krantz P: Substance abuse and psychiatric co-morbidity as predictors of premature mortality in Swedish drug abusers a prospective longitudinal study 1970 - 2006. BMC psychiatry 2011, 11(1):122.
 Hjorthøj C, Østergaard MLD, Benros ME, Toftdahl NG, Erlangsen A, Andersen JT, Nordentoft M: Association between alcohol and substance use disorders and all-cause and cause-specific mortality in schizophrenia, bipolar disorder, and unipolar depression: a nationwide, prospective, register-based study. The Lancet Psychiatry 2015, 2(9):801-808.
 Basso C, Burke M, Fornes P, Gallagher PJ, de Gouveia RH, Sheppard M, Thiene G, van der Wal A: Guidelines for autopsy investigation of sudden cardiac death. Virchows Archiv 2008, 452(1):11-18.
 Tidemalm D, Waern M, Stefansson C-G, Elofsson S, Runeson B: Excess mortality in persons with severe mental disorder in Sweden: a cohort study of 12 103 individuals with and without contact with psychiatric services. Clinical Practice and Epidemiology in Mental Health : CP & EMH 2008, 4:23-23.
 Jones ME, Campbell G, Patel D, Brunner E, Shatapathy CC, Murray-Thomas T, van Staa TP, Motsko S: Risk of Mortality (including Sudden Cardiac Death) and Major Cardiovascular Events in Users of Olanzapine and Other Antipsychotics: A Study with the General Practice Research Database. Cardiovasc Psychiatry Neurol 2013, 2013:647476.